Stone X Group Inc. Magenta Therapeutics, Inc. Transaction History

Stone X Group Inc.

  • $2.29 Trillion
  • Q3 2025

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Aug 13, 2025
BUY
$0.36 - $1.59 $4,405 - $19,456
12,237 New
12,237 $4.83 Million

Others Institutions Holding MGTA

# of Institutions
2
Shares Held
442K
Call Options Held
0
Put Options Held
0
View Full List

About Magenta Therapeutics, Inc.

MGTA Quotes by TradingView
  • Ticker MGTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,890,500
  • Description
  • Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...
More about MGTA
Track This Portfolio

Track Stone X Group Inc. Portfolio

Follow Stone X Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email